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zDHHC S-acyltransferases are enzymes catalyzing protein
S-acylation,acommonpost-translationalmodificationonproteins
frequently affecting theirmembrane targeting and trafficking.The
ankyrin repeat (AR) domain of zDHHC17 (HIP14) and zDHHC13
(HIP14L) S-acyltransferases, which is involved in both substrate
recruitment and S-acylation-independent functions, was recently
shown tobind at least six proteins, by specific recognition of a con-
sensus sequence in them. To further refine the rules governing
binding to theARof zDHHC17,we employedpeptide arrays based
onzDHHCAR-bindingmotif (zDABM)sequencesof synaptosom-
al-associated protein 25 (SNAP25) and cysteine string protein 
(CSP). Quantitative comparisons of the binding preferences of
400 peptides allowed us to construct a position-specific scoring
matrix (PSSM) forzDHHC17ARbinding,withwhichwepredicted
and subsequently validated many putative zDHHC17 interactors.
We identified 95 human zDABM sequences with unexpected
versatility in amino acid usage; these sequences were distributed
among 90 proteins, of which 62 have not been previously im-
plicated in zDHHC17/13 binding. These zDABM-containing
proteins included all familymembers of the SNAP25, sprouty, cor-
nifelin, ankyrin, and SLAIN-motif containing families; seven
endogenousGag polyproteins sharing the same binding sequence;
and several proteins involved in cytoskeletal organization, cell
communication, and regulation of signaling. A dozen of the
zDABM-containing proteins had more than one zDABM
sequence, whereas isoform-specific binding to the AR of
zDHHC17 was identified for the Ena/VASP-like protein. The
large number of zDABM sequences within the human pro-
teome suggests that zDHHC17 may be an interaction hub
regulating many cellular processes.
Protein S-acylation, the reversible attachment of fatty acids
onto cysteines, is a widespread post-translational modification.
The regulatory effects of S-acylation are protein-specific but
this modification typically impacts membrane binding, intra-
cellular trafficking, protein stability, and protein-protein inter-
actions (1–4).
S-Acylation reactions are mediated by the large (24 iso-
forms in humans) zDHHC enzyme family. Collectively, these
enzymes are responsible for themodification of up to 10%of the
proteome (5). However, we currently lack a detailed under-
standing of substrate specificity in the zDHHC family, since
knowledge about the enzymes that modify specific proteins is
sparse.
The zDHHC13 and zDHHC17 enzyme isoforms contain
N-terminal ankyrin repeat (AR)3 domains. ARdomains are typ-
ically involved in protein-protein interactions, and indeed our
previous work (6, 7), and that of others (8–11), demonstrated
that the AR domains of these zDHHC enzymes are involved in
both substrate binding as well as S-acylation-independent
functions.
Efforts to profile zDHHC enzyme substrates and binding
partners have had limited success to date, with proteomics
analysis of zDHHC knock-out samples only revealing a small
number of high-confidence targets (12, 13). This might reflect
the use of gene-trap models with residual zDHHC expression,
or the partial overlap in the zDHHC isoforms that canmodify a
specific protein. To examine zDHHC-substrate specificity and
interactions, we have adopted a different strategy that involves
the identification of a “consensus” recognitionmotif for the AR
domains of zDHHC17 and zDHHC13. We previously showed
that a (VIAP)(VIT)XXQP motif present in several targets of
zDHHC17/13 mediates interaction with these enzymes (7). To
capitalize on this novel observation, we have now undertaken
peptide array mapping to generate a set of sequence rules for
zDHHC17 binding. These sequence rules have allowed the pre-
diction and validation of binding sites in a wide range of cell
proteins. We now term this sequence motif as zDABM
(zDHHC-AR-binding motif).
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Results
Establishment of sequence rules governing binding of
peptides to the AR of zDHHC17
Peptide arrays consisting of 15-mers of SNAP25 and CSP
peptides were constructed, with all amino acids within a 10-a-
mino acid region containing the zDABM serially substituted to
any possible amino acid. Binding of purified His6-tagged AR
domain (residues 51–288) of zDHHC17 (ARzD17-His) to each
of these peptides was subsequently assessed by far-Western
blotting using a histidine tag antibody (Fig. 1). Binding of
ARzD17-His wasmore sensitive to alterations of amino acids at
positions 2–3 and 6–7 for both SNAP25 and CSP peptides;
however, amino acid preferences at position 2 for the ARzD17-
His binding were slightly different for SNAP25 and CSP (e.g.
preference for proline in CSP), whereas additional sensitivity
at position 9 was observed for SNAP25 peptides (Fig. 1). Inter-
estingly, cysteine and methionine could compensate well for
the loss of glutamine at position 6 in both SNAP25 and CSP.
Additionally, as derived from both SNAP25 and CSP arrays,
no amino acid preference for ARzD17-binding was observed at
position 1; amino acids glycine and proline were strongly disfa-
vored at positions 4 and 5; and negatively charged (Asp and
Glu) amino acids were disfavored at positions 8–10.
Prediction of zDABM sequences within the human proteome
To incorporate information derived from both peptide
arrays, position-specific scoringmatrices (PSSMs)were created
for both arrays, based on quantification of far-Western spots,
and a hybrid PSSM was derived from the two matrices; this
PSSM was adjusted to be used as input motif for the search of
human protein sequences that are good matches for this
matrix, using Scansite 3 (supplemental Fig. S1B). A total of
533,409 peptides were scored (Scansite scores ranging from
0.1931 to 2), with only a minority of peptides occupying lower
(and thus best matching) scores (Fig. 2 and supplemental Table
S1).Modified z-scores (number of S.D., below themedian Scan-
site score)were also calculated for each scored peptide. Peptides
having modified z-scores above 6 (Scansite scores below 0.6601)
were considered as high confidence hits; both SNAP25 andCSP,
as well as Huntingtin (HTT) and SNAP23, from the previously
identified zDABM sequences (7), were scored within this range,
which corresponds to only the top 0.11% percentile of the scored
peptides;mediumand lowconfidence levelswere arbitrary chosen
to include peptides havingmodified z-scores between 5 and6, and
between 3 and 5, respectively; within these three confidence levels
all six previously reported zDABM sequences (7) are scored as
good matches for ARzD17-binding (Fig. 2), and this range
accounts for the top 5% percentile of the scored peptides.
Validation of putative zDABM sequences for binding to the AR
domain of zDHHC17
More than 2,600 sequences deriving from the Scansite search
were analyzed for cytosolic localization and disorder (for more
information see ”Experimental procedures“ and supplemental
Table S1). We identified a total of 590 disordered and cytosol-
localized sequences, which were distributed among 224 pro-
teins (supplemental Table S2). 107 of these peptides (distrib-
uted in 96 proteins) were chosen for assessment of binding to
ARzD17-His; these included 51 high confidence sequences, 28
medium confidence sequences, 26 low confidence sequences,
and 2 sequences below the lowest confidence threshold level. 40
of the 107 sequences derived from proteins are either known or
are speculated to be zDHHC17 interactors. One sequence
from the nuclear MAX gene-associated protein (MGAP), for
which no cytosolic localization has been documented, was also
included in peptide synthesis to serve as positive control,
because this was at the top 0.01% percentile, with a Scansite
score below 0.4 and a modified z-score above 7.5. Additionally,
two non-natural peptides were synthesized: one with a highly
favorable ARzD17-binding amino acid sequence, and another
one with a highly disfavorable amino acid sequence (according
to the SNAP25-CSPPSSM); these twopeptides, served as pos-
itive and negative controls, respectively.
12-mer peptides of the 109 sequences mentioned above (Fig.
3E) were synthesized in an array, and their ability to bindARzD17
was assessedby far-Westernblot analysis, using purifiedARzD17-
His and detection with histidine tag antibody (Fig. 3A). A total of
96 natural occurring zDABM sequences were identified. As
expected, the artificial favorable peptide was a strong binder,
whereas binding of the artificial disfavorable peptide to ARzD17
washardlydetected. Surprisingly, the zDABMsequenceofMAP6,
although previously found to be involved in interaction with the
AR domain of zDHHC17/13 (7), was not sufficient to promote
ARzD17 interaction on its own (Fig. 3A), which suggests that
MAP6 may require a sequence greater than 12 amino acids, or
additional domains for stable interactionwith zDHHC17.All high
confidencehits tested (51 sequenceswith z-scores above6, includ-
ing MGAP) were able to bind ARzD17 quite strongly, whereas at
lower threshold levels, a number of weak binders or no-binders
appeared, along with the strong binders (Fig. 3B).
In our effort to identify which sequences of a given protein
may be involved in ARzD17-binding, we included (in our 109
peptide array) two different peptides for the same protein, for
17 of the proteins screened. To our surprise, in 12 of the 17
proteins tested, both peptides could interact with ARzD17 (Fig.
3C). Most of the proteins with confirmed zDABM sequences
are known to be expressed in neuronal cells, and are either
known, or predicted to be palmitoylated (Fig. 3C and supple-
mental Table S2).
To get a good approximation of amino acid preferences for
ARzD17 binding within naturally occurring sequences, occur-
rences of each amino acid at each position were calculated within
all zDABM sequences, including: both verified for ARzD17-bind-
ing protein sequences, aswell as the rest of the 66 high-confidence
hits (which although not verified for binding, are expected to
be true zDABM sequences); the inclusion of the latter group in
the analysiswasdone to compensate for anybias introduced in the
selection of peptides to be verified as zDABM sequences. The
resulting amino acid frequencies for each position reveal an unex-
pected versatility in amino acid usage forARzD17-binding, aswell
as marked absence of particular amino acids (such as Glu, Asp,
Asn, Cys, Phe,Met, Trp, andTyr) in all positions (Fig. 3D). Serine,
on the other handwas themost favorable amino acid, but in posi-
tions less critical for binding. Putative phosphorylation of these
serine residues is expected to negatively affect ARzD17-binding,
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Figure 1. Assessment of aminoacidpreferences for binding to theARdomainof zDHHC17. SNAP25 andCSP 15-mer peptides having all possible amino
acid substitutions within a 10-amino acid region were constructed on peptide arrays. The ability of each peptide to interact with the AR of zDHHC17 was
assessed by far-Western blotting, using a histidine-tagged purified human AR domain of zDHHC17 (ARzD17-His; 51–288 amino acids), and detection using a
histidine tag antibody. Corresponding sequence logos showing preferences for each amino acid within these 10-amino acid stretches were subsequently
created. Signals for eachpeptide spotwerequantified andnormalized against the average signal ofwild-typepeptides for eachprotein. Peptideshaving signal
intensities less than 5% of wild-type peptides were considered non-binders and were penalized with a score of zero; the rest were expressed as frequencies
(normalized so that the sum of scores for each position equals to 1). The derived PSSMs (see supplemental Fig. S1A) were used for the generation of sequence
logos (generated by Seq2Logo; Shannon typewith no clusteringmethod). The highly disfavorable amino acid substitutions (with scores of less than 0.005) for
each position are shown.
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because no negatively charged residues (Asp andGlu) are favored
for binding at equivalent positions. Serine, threonine, and tyrosine
residues within zDABM sequences, whose phosphorylation has
been confirmed, are shown in Fig. 3E.
zDABM sequences are enriched in proteins involved in
cytoskeletal organization and cell communication, and in
certain protein families
To gain insight into the functions that may be regulated by
zDABM-binding, we assessed whether there is enrichment for
certain biological processes or cellular components within the
zDABM-containing proteins. The 89 genes corresponding to
the 90 proteins with zDABM sequences identified (GAK9 and
POK9 derive from the same gene) were thus included for such
analysis, using the PANTHER Classification system and Bon-
feronni correction; this analysis revealed that endogenously
derived zDABM-containing proteins are enriched in cytoskel-
eton, and in functions involved in cytoskeletal organization,
and regulation of signaling and cell communication (Fig. 4A).
Due to the inclusion of 6 retrovirus-derived Gag polyproteins
(which share the same zDABM sequence) in our dataset, signif-
icant enrichment for viral envelope localization and viral pro-
cesses (RNA-dependent DNA biosynthesis and DNA integra-
tion) were also observed (Fig. 4A). To compensate for any bias
thatmay have been introduced by the selection of peptides (and
thus the proteins) to be validated for ARzD17 binding, we
repeated the analysis, including the 66 extra proteins for which
high confidence for ARzD17-binding sequences were found,
but whose sequences were not verified for binding. The only
enrichment that was lost by the inclusion of these proteins was
that for regulation of signaling (Fig. 4B).
We next searched whether zDABM sequences are enriched
in certain protein families. Indeed, we found that, apart from
the SNAP25 family whose two members (SNAP25 and
SNAP23) have already being confirmed to have zDABM
sequences (7), there were additionally 4 protein families with
all members represented in zDABM-containing proteins; these
were: the Sprouty (SPY1–4), Cornifelin (CNFN, PLAC8, and
PL8L1), Ankyrin (ANK1–3), and SLAIN-motif (SLAI1–2) fam-
ilies. Additionally, zDABM sequences were also found in 2
SPRED (Sprouty-related, EVH1-domain containing) proteins
(SPRE1–2), which, like the Sprouty proteins, also have a (puta-
tively highly palmitoylated) C-terminal cysteine-rich Sprouty
domain.
zDABM-containing proteins are able to bind to the AR of
zDHHC17 due to their zDABM sequence
We next assessed whether full-length zDABM-containing
proteins can interact with the AR domain of zDHHC17 (and
zDHHC13), and whether such interactions are truly dependent
on the zDABM sequence. As mentioned above, all Sprouty and
SPRED proteins have a conserved C-terminal Sprouty (SPR)
domain. To assess whether this domain or a zDABM sequence
is involved in zDHHC17 interaction, we utilized both full-
length SPRED2, as well as two truncation mutants lacking,
either the SPR domain, or both the SPR and a region containing
the zDABM sequence (SPRED2 has only one zDABM
sequence). These constructs were assessed for interaction with
both zDHHC17 and zDHHC13 (which we previously showed
to interact with zDABM too) using the mating-based split-
ubiquitin system (SUS) in yeast. As shown in Fig. 5A, all Sprouty
proteins and SPRED1–2 have a homologous zDABM sequence
proximal to their conserved C-terminal SPR domain. Our SUS
assay with the above SPRED2 constructs revealed that both
zDHHC17 and zDHHC13 can interact with SPRED2, and that
this interaction is not dependent on the SPR domain, but on the
region containing the zDABM sequence (Fig. 5B).
Ena/VASP-like protein (EVL) is an actin-associated pro-
tein, recently identified to interact with zDHHC17 in a yeast
Figure 2. Procedure used for the in silico prediction of zDHHC-AR-bind-
ing motif (zDABM) sequences across the human proteome. A hybrid
SNAP25 and CSP PSSM was created, from averaging scores from individual
SNAP25 and CSP PSSMs (derived from quantification of far-Western blots
shown in Fig. 1) and adjusting this PSSM for Scansite, with Pro at position 7
assigned as a fixed amino acid (see ”Experimental procedures“ for details).
The derived PSSM was used for matching peptides across the human pro-
teome (SwissProt database; UniProt release 2011_11). The number of pep-
tides scored and the distribution of peptides for each score are shown.
Selected hits with Scansite scores ranging between 0.2 and 1.4 (see ”Experi-
mental procedures“ for more details) were filtered for cytosolic localization
anddisorder prediction to be included for validation of ARzD17binding. Pep-
tides with a modified z-score (number of S.D. below the median Scansite
score1.663) above6were consideredashigh confidencehits. Thepositions
in the histogram of the six peptides that have been previously shown to bind
to the AR of zDHHC17 and zDHHC13 are shown.
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two-hybrid system (11). Like SPRED proteins, it also
contains an N-terminal WH1 domain, whereas its single
zDABM sequence contains at position 3 the disfavorable
ARzD17-binding amino acid leucine. In our attempt to
clone isoform 1 of EVL for assessment of zDHHC17-binding,
we also isolated a novel isoform (isoform 5), which is lacking
a 21-amino acid stretch containing the EVL zDABM
sequence (Fig. 6A); the cDNA sequence of this isoform has
been submitted to GenBankTM (accession number KY819016),
and its translation product corresponds to EVL isoform 5
(Q9UI08-5 entry in UniProt). ARzD17-His pull downs of
HEK293T lysates expressing these two EGFP-EVL isoforms
revealed that only EVL isoform 1 (EVL-1), which has the
zDABM sequence, can bind to the AR domain of zDHHC17,
whereas EVL isoform 5 (EVL-5), which lacks a zDABM, cannot
(Fig. 6B).
Figure3.ValidationofpredictedzDABMsequences.Apeptidearraywasconstructedcomprisinga totalof10912-merpeptides,whichcorrespondto107human
sequences, and two artificial sequences: one expected to bind ARzD17 (favorable peptide) and one not expected to bind (disfavorable peptide). Binding to ARzD17
was assessed by far-Western blotting using purified human ARzD17-His (51–288 amino acids) and detection with a histidine tag antibody. Quantified signals were
normalizedtothehighestobservedsignal,whichwasgivenanarbitraryvalueof1000;peptideswithvalues less than10wereconsiderednon-binders.A,peptidearray
far-Western blot. B, normalized signal intensities were plotted against the Scansite-derived score. Peptides below the red line (log values1) were considered as
non-binders; whereas peptides below the dashed orange line (log values1.5) were considered as weak binders. The total numbers of binding and non-binding
peptides, aswell as thepositionof SNAP25andCSP in theplot, are shown.C,bargraph showing the total numberofproteins containing zDABMsequences and the
number that are known to be neuronal, palmitoylated (SwissPalm database), or predicted to be palmitoylated (palmitoylation sites were predicted by CSS Palm 3.0
usinghighthresholdsetting), aswell as thenumberofproteins thatcontain twozDABM-bindingsitesasopposedtoonesite (thenuclearproteinMGAPwasexcluded
from these analyses).D, comparisonbetween the amino acid preferences definedby thehybrid SNAP25-CSPPSSM, and the amino acid preferences definedby the
projected amino acid frequency for eachposition of zDABM-binders. For the projected amino acid frequencies, the remaining high-confidence sequenceswere also
consideredontopofall thenaturalpeptides identifiedaszDABMsequences. Themorecriticalbindingpositionsarehighlighted in red,withallbutdisfavorableamino
acids for these positions shown; favorable-only amino acids for all other positions are indicated too. Amino acidswithin themotif that appear highly disfavorable (in
at least 7/10 positions) or favorable (in at least 5/10 positions) are highlighted in a box. E,peptides used at the corresponding locations on the peptide array, with the
most critical for binding positions highlighted; corresponding peptide positions for each peptide within human proteins are shown. Residues that are known to be
modifiedbyphosphorylation (PhosphoSitedatabase)are indicated inbold.Non-natural zDHHC17-interactors (proteins thatareonlyknowntobenuclearandartificial
peptide sequences) are shown in red.
Figure 4. Gene Ontology (GO) biological processes and cellular components enrichedwithin proteins possessing zDABM sequences. A, the 89 genes
corresponding to the 90 proteins with zDABM sequences were analyzed for enrichment of biological processes and cellular components using the PANTHER
Classification system. GO processes/components that were enriched by 2-fold or more and were deemed statistically significant (p 0.05) after Bonferroni
correction, are indicated, alongwith the proteins counts for eachGO entry. Enriched parental GO termswith the same observed proteins are not shown. B, the
same analysis was performed as in A, but this included the 66 genes corresponding to proteins having high confidence for zDHHC17-binding sequences
(modified z-scores above 6) as well, but whose corresponding peptides were not verified for ARzD17-binding.
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PAIR-BP1 and SLAIN1 are able to interact with the zDHHC17
despite possessing non-favorable amino acids within their
zDABM sequences
Because a number of peptides with non-favorable amino
acids at critical for binding positions came up as ARzD17-bind-
ers, we were particularly interested in assessing if proteins con-
taining them are able to interact with zDHHC17 as well. Thus,
apart from EVL isoforms 1 and 5, we also cloned and subse-
quently expressed in HEK293T cells EGFP-tagged versions of
human PAI-RBP1 (plasminogen activator inhibitor 1 RNA-
binding protein) and SLAIN1 (SLAINmotif-containing protein
1). PAI-RBP1 presumably utilizes 2 different sequences for
ARzD17-binding, and both of them have arginine instead of
glutamine at position 7; SLAIN1 on the other hand, may use
2–3 different sequences for ARzD17-binding, each having
unfavorable amino acids at positions 2–3 (Fig. 7A). All isoforms
of these proteins contain the above zDABM sequences, includ-
ing the shorter versions used in this experiment (isoform 2 of
SLAIN1 and isoform 3 of PAIBP1). ARzD17-His pull downs of
HEK293T lysates expressing the above proteins revealed that
both PAI-RBP1 and SLAIN1 can bind to the AR domain of
zDHHC17 (Fig. 7B), whereas co-immunoprecipitation assays
showed that these proteins also form complexes with full-
length zDHHC17 (Fig. 7C).
Discussion
In this study we have evaluated binding of a large number of
peptides (based on amino acid sequences of SNAP25 and
Figure 5. Ahomologous region amongall Sproutyproteins andSPRED1–2,which is locatedproximal to the Sproutydomain, is required for SPRED2-
zDHHC17/13 interaction. A, domain architecture ofmurine SPRED2 showing the position of the homologous zDHHC17-binding sequence shared among all
Sprouty proteins and SPRED1–2 (WH1, WASP-Homology 1; KBD, c-Kit-bindingdomain; SPR, Sprouty domain).Mouse SPRY1–4 and SPRED1–2proteins (UniProt
entries shown in parentheses) were aligned using Clustal Omega, and the alignment corresponding to 252–300 amino acids of SPRED2 is shown, with
blue-shaded areas indicating identical amino acids in 3 or more proteins. B, interaction of wild-type murine SPRED2, and two C-terminal truncations, with
murine zDHHC17 and zDHHC13, as assessed by themating based SUS. In this system, ubiquitin is split in half, with the N-terminal half (Nub) attached to a prey
protein (SPRED2 here), whereas the C-terminal half (Cub) is fused between amembrane-bound bait protein (zDHHC17 or zDHHC13 here) and the PLV (Protein
A, LexA, VP16 fusion) transcription factor. Matings co-expressing zDHHC17/13 and SPRED2 are able to grow inmedia lacking adenine and histidine only upon
the zDHHC-SPRED2 interaction, because the latter will lead to the reassembly of ubiquitin, its recognition by ubiquitin-specific proteases, and the subsequent
cleavage and translocation of the PLV transcription factor to the nucleus, where it can activate genes essential for adenine and histidine synthesis. The I13G
substitution on Nub (NubG versus NubI) prevents spontaneous reassembly of the two ubiquitin halves in the absence of interaction. Protein levels of NubG-
2HA-SPRED2 constructs (shown on the right) were assessed by an HA antibody.
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CSP) to the AR domain of zDHHC17. The binding profile of
this comprehensive set of peptides enabled us, not only to con-
struct a sequence rule-based consensus for ARzD17 binding,
but also to search for and subsequently validate a large number
of human sequences as zDABM-bearing sequences. The strik-
ing preference for specific amino acids at positions 2–3 (ali-
phatic ones) and 6–7 (QP dipeptide) within zDABM sequences
observed before (7) has been confirmed here (Fig. 1). Indeed a
very recent structural study (Ref. 14; published while this paper
was under review) showed that the above residues in SNAP25
zDABM form a number of important contacts with a region
between ankyrin repeats 1 and 3 of zDHHC17; more specifi-
cally, interactions between, Val-113 and Pro-117 of the ana-
lyzed SNAP25 peptide, and Asn-100 and Trp-130, respectively,
of zDHHC17, were found to be particularly important. Never-
theless, despite the striking preference for particular amino
acids in these positions, a large number of peptides having non-
favorable amino acids at those positions are still able to bind
strongly to ARzD17. The favoritism for certain amino acids at
various positions thus seems to be influenced by the surround-
ing amino acids within the zDABM sequence: for example, the
amino acid sequence of the SNAP25 zDABMhas a strong pref-
erence for lysine or arginine at position 9, whereas the CSP
zDABM permits a wider variety of residues at this position; the
CSP zDABM also strongly favors proline and alanine at posi-
tion 2, which are either less favored or disfavored for ARzD17-
binding, respectively, in the SNAP25 sequence; similarly, the
disfavored dipeptide sequences at positions 2–3, YP and SK,
appear to be permitted/favored in the zDABM sequences of
PDE4D (Pro-46) and SLAIN1 (Pro-541), respectively. zDABM
sequences thus appear very versatile in the usage of amino
acids.
Although the sequence assessment of non-binders and bind-
ers could hardly indicate amino acids that are absolutely detri-
mental for ARzD17-binding, the binding pattern of the over
500 peptides tested in our study reveals marked preferences for
particular amino acids at certain positions, and at the same time
strong lack of preference for other amino acids (Asn, Asp, Glu,
Cys, Phe, Met, Trp, and Tyr) at all positions tested; the latter
partly reflects the propensity of certain amino acids (Cys, Phe,
Met, Trp, and Tyr) not to be present in disordered regions (15).
The strong preference for positively charged residues (Arg and
Lys) over negatively charged ones (Asp andGlu) at certain posi-
tions (4 and 9), as well as the general lack of preference of
negatively charged residues, indicates the possible existence
of a negatively charged patch in or around the zDABM-
binding pocket in zDHHC17. Indeed, Glu-89 and Asp-122 of
zDHHC17, which contribute to the interaction with the
zDABM sequence of SNAP25, may provide the negative charge
involved in favoring positive over negative charged residues in
zDABM sequences (14). Additionally, a strong preference for
serine residues at the less critical binding positions was
observed within the confirmed and highly predicted sets of
zDABMsequences. Putative phosphorylation of these serines is
expected to impair binding to the AR domain of zDHHC17/13.
A phosphorylation-dependent binding switch-off has been pre-
viously documented for theAnkyrin repeat ofANKRA2 and the
phosphorylated LYTSP(pS)LPNITL sequence of HDAC4 (16).
Unexpectedly, cysteine andmethioninewere found to compen-
sate reasonably well for the lack of glutamine at position 7. The
reason for that is unclear, becauseGln-116 of a SNAP25peptide
is involved in hydrogen bonding with Glu-89 and Asp-122 of
zDHHC17 (14), and both cysteine and methionine would be
unable to substitute these bonds. It is possible that some sub-
stitutions force peptides to create new bonds, originally absent
in wild-type proteins, and such flexibility in new bond forma-
tion was recently shown for Gln-116 of SNAP25 upon
zDHHC17 binding (14).
Despite the versatility of amino acid usage at critical binding
positions of zDABM sequences, our approach could accurately
predict a large number of zDABM sequences, with 100% accu-
racy (51 tested) for peptides with modified z-scores above 6
(Scansite scores below 0.6601). In total, we were able to identify
zDABM sequences in 28 of the known and speculated
zDHHC17/13 interactors, and in 62 proteins not previously
implicated in zDHHC17/13-binding. Seven of these novel
zDHHC17 interactors are retrovirus group K Gag polyproteins
sharing the same zDABM sequence. Increased mRNA levels
of such proteins have been linked with cancer and a number
of autoimmune and neurological diseases (17). Whether
zDHHC17-binding can enhance or prevent such processes
remains to be found. Other families whose members were
enriched among zDABM-containing proteins were: the
Sprouty, Ankyrin, Cornifelin, and SLAIN-motif families,
Figure 6. A novel EVL isoform lacking the zDABM sequence is unable to
interact with the AR domain of zDHHC17. A, domain architecture of EVL
isoforms 1 and 5 (WH1, WASP-homology 1; EVH2, Ena/VASP-homology 2).
Isoform 5 is missing a 21-amino acid region (shown in red) containing the
zDABM sequence (amino acid sequence of this stretch is shown with the
critical for ARzD17-binding positions indicated in red). B, EGFP-tagged EVL-1
and EVL-5 human proteins were expressed in HEK293T cells, and their ability
to interact with the AR domain of zDHHC17 was assessed by pull downs of
corresponding lysates by ARzD17-His (51–304 amino acids of human
zDHHC17). 7.5% of total inputs and 40% of total bound fractions were run on
12% gels, and following transfer, blots were stained by Ponceau S solution
and probed with a GFP antibody.
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whereas 2 members of the Sprouty-related EVH1-domain
containing (SPRED) protein family were identified to have
zDABM sequences.
Sprouty and SPRED proteins are known to be negative regu-
lators of MAPK signaling and may thus function as tumor sup-
pressors (18, 19), whereas SPRED1 and SPRED2 have been
additionally found to be negative regulators of hematopoiesis
(20, 21). Because zDHHC17 has an oncogenic potential upon
overexpression (22) and is up-regulated in cells overexpressing
an essential hematopoiesis transcription factor (23), it is
expected that the interaction of zDHHC17 with Sprouty and
SPRED proteins would negatively regulate the functions of the
latter.
Ankyrins are major scaffolding proteins that coordinate
membrane transporters and cell adhesion proteins within
plasma membrane compartments (24); these functions depend
heavily on Ankyrin palmitoylation, but among all zDHHC
S-acyltransferases, only zDHHC5 and zDHHC8 were found to
be able to mediate Ankyrin 3 palmitoylation (25). Hence, the
interaction of zDHHC17with Ankyrins either serves some cur-
rently unknown S-acylation-independent functions, or medi-
ates S-acylation of proteins attached to Ankyrins.
Cornifelin (CNFN) is a component of the cornified envelop
with high expressions in skin, uterus, and cervix (26). This pro-
tein was recently found to be palmitoylated on 5 different sites
and to be a substrate of zDHHC13 (27); because zDHHC17 has
been shown to have greater activity than zDHHC13 for all
interacting proteins tested (6, 28, 29), it is expected that
zDHHC17 is able to palmitoylate Cornifelin as well. The pla-
centa-specific gene 8 protein (PLAC8) and PLAC8-like protein
1 (PLAC8L1) also belong to the Cornifelin family. Both pro-
teins, like Cornifelin, have four predicted palmitoylation sites
(supplemental Table S3) and an N-terminal zDABM sequence.
Hence, these are also likely to be palmitoylated by zDHHC17
and zDHHC13. Although PLAC8 seems to have functions
important for a range of processes like immunity (30), brown
and white fat cell differentiation (31, 32), and autophagy (33),
the function for PLAC8L1 is currently unknown.
SLAIN-motif proteins (SLAIN1 and SLAIN2) are enriched in
brain and promote microtubule growth by recruiting the
microtubule polymerase ch-TOG to microtubule plus-ends
(34). Furthermore, loss of function mutations of SLAIN1 (as
well as ofMAPK8,whichwas also identified as zDABM-protein
in our screening) are associated with intellectual disability (35).
How the zDHHC17 interaction with SLAIN-motif proteins
regulates these functions is currently unknown.
SLAIN-motif proteins and Ankyrins are only some of the
many neuronal zDABM-containing proteins with roles in cyto-
skeletal organization and regulation of cell communication,
respectively, whereas proteins that regulate signaling, like
SPRED and Sprouty, are also very common among zDABM
proteins. Importantly, these three processes often converge,
especially in brain cells, with neurons executing their function
by efficiently communicating with other neurons, as well as
glial cells, and transmitting various signals either intracellularly
or extracellularly via a network of cell adhesion proteins and
cytoskeleton-associated proteins. Hence zDHHC17 may be an
important regulator of communicative networks in the brain.
Indeed, a sharp decrease in zDHHC17 expression in mice
results in numerous behavioral and synaptic deficits (36, 37),
which get more severe and become incompatible with life,
when zDHHC17 is completely lost (38). These deficits are asso-
Figure 7. PAI-RBP1 and SLAIN1 are able to bind to zDHHC17, despite possessing disfavorable amino acids within their zDABM sequences. A, con-
firmed and speculated zDABM sequences of PAI-RBP1, SLAIN1, and SLAIN2 are shown, with amino acids located at critical binding positions shown in red and
disfavorable aminoacids (according toSNAP25andCSPPSSMs) indicated inbold (NT, not tested). These zDABMsequences exist in all known isoformsof these
proteins. The proline position corresponds to the location of the zDABM in the canonical sequence for each protein. B, EGFP-tagged PAI-RBP1 and SLAIN1
human proteins (isoforms 3 and 2, respectively) were expressed in HEK293T cells, and their ability to interact with the AR domain of zDHHC17was assessed by
pull downs of corresponding lysates by ARzD17-His (51–304 amino acids of human zDHHC17). 7.5% of total inputs and 40% of total bound fractions were run
on 12% gels, and following transfer, blots were stained by Ponceau S solution and probed with a GFP antibody. C, lysates of HEK293T cells co-expressing
HA-zDHHC17andEGFP, EGFP-taggedPAI-RBP1 (isoform2), or EGFP-taggedSLAIN1 (isoform3)were subjected to co-immunoprecipitationusingHAbeads. 6%
of the total inputs and 25% of the immunoprecipitated fractions were resolved on 10%polyacrylamide gels and then visualized byWestern blotting using HA
and GFP antibodies.
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ciated with striatal dysfunction, astrogliosis, and microgliosis
(38). The regulation of actin- andmicrotubule-based processes
by zDHHC17 in neurons is probably reflected by the fact that,
loss of zDHHC17 in zebrafish, neuronal stem cells, or PC12
cells causes defects in axonal outgrowth (39). The actin-associ-
ated EVL protein is a recently identified zDHHC17 interactor
(11), which is involved, along with other Ena/VASP proteins, in
neuritogenesis and axon formation (40). Rat cortical neurons
and glial cells contain two alternatively spliced isoforms of EVL
differing in a 21-amino acid sequence (41), whereas similar
alternatively spliced products are also reported in frogs (42).
Here, we show that alternatively spliced products differing in
this sequence exist in humans too, and that the AR of
zDHHC17 can only bind EVLwhen this extra sequence is pres-
ent; thus EVL binding to zDHHC17 can serve functions associ-
ated only with the longer EVL isoform. The latter isoform has
been reported to be phosphorylated by protein kinase D on this
extra sequence (43), but distal to the zDABM sequence. The
exact role of themodification is not known; however, the phos-
phorylated EVL longer isoform was found to be enriched in
tight cell junctions (43).
Unexpectedly, a zDABM-containing peptide of the microtu-
bule-associated protein 6 (MAP6)was not sufficient for binding
to the AR domain of zDHHC17. This sequence is known to be
implicated in ARzD17/13-binding, because alanine substitu-
tion of the conserved proline does impair binding (7). Hence,
the zDHHC17/13-MAP6 interaction may require either a
longer MAP6-peptide sequence than typically required for
zDABMs, or a second interface to stabilize the interaction. It is
currently established that structures comprised of 4–6 ankyrin
repeats can support binding of up to 8-amino acid peptide
stretches (16, 44–46), whereas considerably longer peptide
sequences of sodium channel Nav1.2 and Neurofascin pep-
tides (28 and 95 amino acid peptides, respectively) are required
for efficient interaction with the 24 ankyrin repeats of Ankyrin
proteins (47). Thus the 7 ankyrin repeats of zDHHC17 and
zDHHC13 AR domains may be able to accommodate slightly
longer than 8-amino acid long sequences, with the exact length
being dependent on the individual sequence of each protein. In
the case of SNAP25, a longer than 10-amino acid sequence
seems to be required for maximal zDHHC17-binding, because
a 10-amino acid stretch of SNAP25 could not support a strong
interaction with the ARzD17, as full-length SNAP25 could (7,
14). Additionally, the analysis of amino acid frequencies among
zDABM-containing proteins has been revealed as disfavorable
for ARzD17-binding amino acids in the whole 12-amino acid
stretch assessed (Fig. 3D), which indicates that many proteins
may need sequences of 12 amino acids or longer for efficient
ARzD17-binding.
In this work we found that the AR of zDHHC17 could inter-
actwith twodifferent sequences located in the sameprotein, for
at least 12 of the 17 proteins tested. Thus a greater number of
zDHHC17 binders with two zDABM sequences may poten-
tially exist.Moreover, given thatmore than 10 putative zDABM
sequences per protein were found for certain proteins (supple-
mental Table S2), it is possible that zDHHC17 may recognize
more than 2 sequences within these and other proteins. The
above indicate that the AR domain of zDHHC17 (and poten-
tially of zDHHC13) has the capacity to engage with a given
number of proteins in different ways, thus forming different
complexes according to the way that each protein is presented
to its AR domain. This means that blockage of zDHHC17 bind-
ing onone site of a protein (i.e.by phosphorylation or binding to
another protein) may result on this protein being bound to
zDHHC17 using a different site; thismay subsequently result in
a different function executed due to this alternative binding.
The ability of zDHHC17 to bind such a large number of
sequences with relaxed rules for binding may thus enable this
enzyme to bind a plethora of proteins under different orienta-
tions; zDHHC17 may thus be a hub for many interactions
responsible for dynamic regulation of a multitude of processes.
Experimental procedures
Chemicals and antibodies
Unless otherwise stated, all chemicals were purchased from
Sigma (Dorset, UK). Mouse His6 tag antibody (ab18184) was
from Abcam (Cambridge, UK), rat HA from Roche Applied
Science (Sussex, UK), and mouse GFP (JL8) from Clontech.
Secondary IRDye mouse antibodies were from LI-COR (Cam-
bridge, UK).
Cloning, mutagenesis, and protein purification
With the exception of human ARzD17-His protein (His-
tagged ankyrin-repeat domain of zDHHC17), which is
described below, and murine zDHHC17 in HA-pEF-BOS,
which was kindly provided by Masaki Fukata (48), all cDNAs
were cloned by Gateway technology (6), using the manufactu-
rer’s kits and instructions (Life Technologies, Paisley, UK). PCR
and site-directed mutagenesis reactions for insertion of STOP
codons were performed using a KOD hot-start polymerase kit
according to the manufacturer’s guidelines (Merck Millipore,
Watford, UK). Primers for introducing Gateway compatible
adapters by PCR (attB-PCR) were purchased from Life Tech-
nologies, whereas primers for site-directed mutagenesis, or
PCR amplification with restriction adapters, were purchased
from Sigma. All site-directed mutagenesis reactions occurred
in entry clones and were confirmed by sequencing (GATC ser-
vice, Constance, Germany). Original cDNAs used for cloning
were as follows: human zDHHC17 was provided by Michael
Hayden (49),murine zDHHC17 and zDHHC13 (DHHC22)was
provided byMasaki Fukata (48), murine SPRED2 was provided
by Akihiko Yoshimura (50), whereas human SLAIN1 (isoform
2), PAI-RBP1 (isoform 3), and EVL (isoforms 1 and 5) were
isolated from a human embryonic cDNA brain library.
Although isoform 2 of SLAIN1 and isoform 3 of PAI-RBP1 are
lacking sequences present in the canonical isoforms of these
proteins, they both have all the zDABM sequences predicted in
the canonical isoforms.
For the production of pET303-ARzD17-His plasmid, a
human zDHHC17 cDNA fragment (encoding for either 51–288
or 51–304 amino acids) was amplified by PCR using appropri-
ate primers containing also the XbaI and XhoI restriction sites,
and the resulting PCR product was subcloned into pET303CT-
His plasmid (Life Technologies), following XbaI and XhoI
digestion. The resulting protein (51–288 or 51–304 amino
acids of human zDHHC17, followed by a Leu-Glu linker and a
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His6 tag) was purified from transformed BL21(DE3)pLysS bac-
terial cells (Life Technologies), as described previously for
murine His6-ARD17 (7). Protein concentration was estimated
by Nanodrop 2000c measurement.
Far-Western blots
Peptide libraries were produced by automatic SPOT synthe-
sis (51). They were synthesized on continuous cellulose mem-
brane supports on Whatman 50 cellulose membranes using
Fmoc (9-fluorenylmethyloxycarbonyl) chemistry with the
AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments,
Berlin) (52). The SNAP25 and CSP arrays consisted of 15-mer
peptides (200 peptides each), with all possible amino acid sub-
stitutions within a 10-amino acid stretch (sequences and serial
substitution shown in Fig. 1). The dried membranes were sub-
merged in 100% ethanol for 2 min, washed briefly with distilled
water, and then incubated with blocking buffer: 5% (w/v) milk
in PBS-T (PBS containing 0.02% Tween) for 2 h at room tem-
perature. Then, after a brief washing with PBS-T, overnight
incubation with the ARzD17-His protein (500 nM in PBS-T)
took place at 4 °C. Membranes were then washed extensively
with PBS-T, incubated with mouse His6 tag antibody (1/2,000
dilution in PBS-T) for 1 h at room temperature, washed again
with PBS-T, incubated with mouse secondary antibody
(1/10,000 dilution in PBS-T), and after extensive washes with
PBS-T containing 0.2% Tween, ARzD17-His-bound peptides
were visualized using a LI-COR infrared scanner. Spots were
quantified using Image Studio software (version 2.0), with an
area of the blot containing no peptide assigned as background.
PSSMs
Derived signals from quantification were normalized against
the average signal intensity of wild-type peptides for either
SNAP25 or CSP. Peptides displaying signals that were less
than 5% of average wild-type intensities were considered non-
binders and were thus given a score of: (a) zero for PSSMs to be
used for generation of sequence logos, or (b) a score of 0.05 for
PSSMs intended to be used for Scansite. The rest of the signals
were expressed as frequencies: signals were normalized so that
the sum of scores for each peptides equals (a) 1 for each posi-
tion for PSSMs used for sequence logo generation (supplemen-
tal Fig. S1A), or (b) 20 in PSSMs to be used for Scansite search.
For Scansite search, a hybrid PSSMwas subsequently produced
by averaging each of the scores (ranging from 0.05 to 20) from
SNAP25 and CSP PSSMs. Proline at position 7 was then
assigned as the fixed residue: the Pro substitution was given a
score of 21 in the hybrid PSSM, whereas all other substitutions
at that position were given a score equal to zero (supplemental
Fig. S1B).
In silico prediction of zDABMhuman sequences
The hybrid SNAP25-CSP PSSM (with the Pro assigned as
fixed residue at position 7) was selected as the “input motif” in
Scansite 3 for the search of human sequences (SwissProt data-
base; 2011_11 release) matching this motif. Modified z-scores
(number of S.D. below the median Scansite score) were also
calculated for each peptide. Because zDABM sequences are
positioned within disordered regions (7), and they need to
be cytosolic to physically interact with zDHHC17 (and/or
zDHHC13), selected hits were validated for disorder and cyto-
solic localization; these included all sequences from proteins
with modified z-scores above 6, and a number of sequences
withmodified z-scores above 3, including other sequences from
the above proteins, all known and speculated zDHHC17/zD-
HHC13 interactors, and a few randomly selected peptides/pro-
teins. Some of the sequences with modified z-scores ranging
from 1.5 to 3, derived from all the above proteins, were also
analyzed. The known and speculated zDHHC17 interactors to
be analyzed were picked from the zDHHC17 interactor list
reviewed by Butland et al. in 2014 (11), and the most recently
identified interactors and substrates of zDHHC17 (39, 53, 54).
Additionally, proteins whose palmitoylation was decreased in
zDHHC17-deficient mice (13), the known zDHHC13 substrate
cornifelin (27), and related proteins were also included in the
analysis.We first excluded sequences for which luminal, nucle-
ar-only,mitochondrial, peroxisomal, and extracellular localiza-
tion has been shown/proposed, as well as those that are pre-
dicted to be within transmembrane helices, or are located in
regions previously crystallized (and are thus structured). For
the remaining sequences in our list, we predicted disorder
using either the DISOPRED3 tool (within the PSIPRED server;
bioinf.cs.ucl.ac.uk/psipred/),4 or the PrDOS tool (Protein Dis-
Order Prediction; prdos.hgc.jp/cgi-bin/top.cgi),4 these two
have been evaluated as the two most reliable disorder predic-
tion tools, among the 28 prediction groups tested, by the recent
Critical Assessment of techniques for protein Structure Predic-
tion, CASP10 (55). From the sequences predicted to be cytoso-
lic and disordered (at least 8 amino acids with a 10-amino acid
stretch with Pro at position 7), 51 of the predicted top-scoring
hits (modified z-scores above 6), and 56 other sequences with
lower scores were synthesized as 12-mer peptides (positions
0–11) to be validated for ARzD17 binding.
SUS
5l of yeast matings expressing both zDHHC-Cub-PLV bait
and NubG-2HA-tagged prey at corresponding optic densities
(A600) were dropped on synthetic defined (SD) media, to assess
interactions, and on SDmedia supplemented with adenine and
histidine to verify equal optical density among matings. The
SUS principle is briefly described in Fig. 5B, legend; the proce-
dures for yeast transformation, selection of plasmids, yeast-
mating, as well as yeast media formulations have been
described before (7, 56).
Pulldown assays
For ARzD17-His pull downs, HEK293T cells expressing the
corresponding EGFP-tagged proteins in 6-well plates were
lysed by addition of 600 l of lysis buffer (20 mM Tris-HCl, pH
8, 150 mM NaCl, 1% Triton X-100, 20 mM imidazole); 200 l of
the corresponding lysate was then diluted in 1 ml with lysis
buffer without Triton, and diluted lysates were incubated with
25l of nickel-nitrilotriacetic acid-agarose resin (Qiagen,Man-
chester, UK), and 31 l (50 g) of ARzD17-His (or equivalent
4 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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volume of ARzD17-His buffer) for 2 h at 4 °C. After extensive
washing with washing buffer (20 mM Tris-HCl, pH 8, 300 mM
NaCl, 1%Triton, 40mM imidazole), bound proteinswere eluted
by boiling in 50 l of Laemmli sample buffer. 7.5% of total
inputs and 40% of total bound fractions were run on 12% SDS-
polyacrylamide gels, and following electrophoresis and transfer
to nitrocellulose, bound ARzD17-His was detected by Ponceau
S staining and EGFP-tagged proteins byWestern blotting using
a GFP antibody.
Co-immunoprecipitations
For co-immunoprecipitation assays, HEK293T cells in 24-
well plates were co-transfected with murine zDHHC17 in HA-
pEF-BOS plasmid (or empty vector) and EGFP, EGFP-PAI-
RBP1, or EGFP-SLAIN1 plasmids in triplicate wells. Following
24 h, cells in eachwell were lysed in 100l of lysis buffer (Milte-
nyi Biotech) and lysates from three identical wells were pooled
for co-immunoprecipitation assays. Protein isolation was per-
formed using MACS HA Isolation kit (Miltenyi Biotec),
according to themanufacturer’s protocol; however, to preserve
binding of proteins to HA-zDHHC17, all washes were per-
formed in lysis buffer.
Author contributions—K. L. and L. H. C. designed the experiments.
L. H. C. performed the immunoprecipitation experiments described
in the legend to Fig. 7C. K. L. performed all other experiments and
subsequent analyses. R. M. and G. B. constructed the peptide arrays.
K. L. and L. H. C. wrote the manuscript. All authors approved the
final version of the manuscript.
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